Wire · opportunities
Finerenone Approval Expands CKD Care in Type 1 Diabetes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Finerenone (Kerendia) has received FDA approval as the first new therapy in about 30 years specifically for chronic kidney disease (CKD) in adults with type 1 diabetes, based on dedicated phase 3 trial data from FINE-ONE. The approval addresses a gap due to previously limited evidence and coverage challenges, highlighting the importance of routine urine albumin-to-creatinine ratio (UACR) screening to identify candidates for treatment.
This Wire brief sits within Fusion42's coverage of Health, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You have a new FDA-approved kidney treatment for your type 1 diabetes patients that relies on detecting protein in urine, so call the clinics where screening is low and push for routine tests now.
◆ Coverage
5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics